Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545175 | 0.87 | HSD11B1 (0.51) | OPRM1HSD11B1SLC18A3 | |
| SCHEMBL10274482 | 0.84 | OPRM1 (0.67) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL2550 | 0.84 | HDAC4 (0.54) | OPRM1HSD11B1 | |
| SCHEMBL13267655 | 0.83 | HDAC4 (0.57) | OPRM1SLC6A4HSD11B1 | |
| SCHEMBL16565533 | 0.83 | OPRM1 (0.63) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL12104025 | 0.83 | OPRM1 (0.63) | OPRM1HSD11B1 | |
| SCHEMBL12227099 | 0.81 | OPRM1 (0.62) | OPRM1HSD11B1 | |
| SCHEMBL29384359 | 0.81 | DRD3 (0.52) | OPRM1ADRA1A | |
| SCHEMBL684441 | 0.80 | DRD2 (0.51) | OPRM1HSD11B1 | |
| SCHEMBL8226666 | 0.79 | OPRM1 (0.59) | OPRM1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | OPRM1 3168/4885SLC22A1 3303/4885SLC6A4 2692/4885 |
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DTYMK, TK1, PIK3CA | OPRM1 4473/4885SLC22A1 2849/4885SLC6A4 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.